Search

Displaying results 3111 - 3120 of 10000 in total
  1. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis [L1876]. … Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha [L1874].

    Synonyms: 17-hydroxy-7alpha-methyl-19-nor-17alpha-pregn-5(10)-en-20-yn-3-one
  2. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). … As an experimental drug, 2-deoxyglucose was demonstrated to work as an anticonvulsant in temporal lobe epilepsy.

  3. Drug

    Black cohosh

    go.drugbank.com/drugs/DB13975
    Approved

    [L2303] Hormone replacement therapy (HRT) is the standard treatment for early symptoms in post-menopausal women, however, increases the risk of stroke, heart diseases, as well as breast cancer in older … in treating the symptoms of sleep and mood disturbance, and hot flushes.

  4. Drug

    Decamethonium

    go.drugbank.com/drugs/DB01245
    Approved

    Decamethonium is used in anesthesia to cause paralysis. It is a short acting depolarizing muscle relaxant. … It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

    Synonyms: Decamethonium ion, N,N,N,N',N',N'-hexamethyl-1,10-decanediaminium
  5. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine. … Dexchlorpheniramine has more pharmacological activity than the R and so is more potent than the racemic mixture.

  6. Drug

    Clesrovimab

    go.drugbank.com/drugs/DB18877
    Approved

    [A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233] … [L53233] As there are no RSV vaccines approved for infant patients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed

  7. Drug

    Difluocortolone

    go.drugbank.com/drugs/DB09095
    ApprovedWithdrawn

    Difluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. … It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

  8. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    [L4168] It was approved for the same indications in Canada in June 2022. … Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma.[A36741]

  9. Drug

    Fezolinetant

    go.drugbank.com/drugs/DB15669
    ApprovedInvestigational

    [A259542] Fezolinetant was approved by the FDA in May 2023 under the brand name Veozah.[L46422] It was subsequently approved by the EMA in December 2023 for the same indication.[L50086] … [A259606] Estrogen is a potent neuromodulator, particularly in the hypothalamus, and has been shown to be involved as a negative regulator in generating Gonadotropin-releasing hormone (GnRH) pulse through

  10. Drug

    Pexidartinib

    go.drugbank.com/drugs/DB12978
    ApprovedInvestigational

    In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. … [A182243] Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.[L7901]